Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Breast03
jRCT2061220087Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of datopotamab deruxtecan, durvalumab, capecitabine and pembrolizumab in triple-negative breast cancer (TNBC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Invasive disease-free survival for datopotamab deruxtecan + durvalumab versus investigator's choice therapy. Started Mar 2023; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2061220087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061220087.